United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
United Therapeutics Corp. (UTHR) PT Raised to $235 at Cowen
August 4, 2021 12:22 PM EDTCowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $235.00 (from $230.00) while maintaining an Outperform rating following results.
The analyst commented, "Q2 financials came in above consensus expectations on the top and bottom line, supported by strong performance from... More
United Therapeutics (UTHR) Tops Q2 EPS by $1.07
August 4, 2021 6:09 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $4.09, $1.07 better than the analyst estimate of $3.02. Revenue for the quarter came in at $446.5 million versus the consensus estimate of $378.75 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More